AOD-9604 Overview
Category:
Peptide (C-terminal fragment of human growth hormone)
How it works:
Mimics the lipolytic (fat-breaking) domain of human growth hormone (hGH) to stimulate lipolysis and fat oxidation while (in theory) avoiding full GH receptor activation and its erythropoietic/insulin-antagonistic effects.
Alternative names:
AOD-9604, “hGH fragment 177-191” (C-terminal hGH hexadecapeptide)
Primary research focus:
- Weight-loss / fat-metabolism agent
- Metabolic health adjunct
Potential risks:
Mixed efficacy in larger trials (some early positive signals, later larger trials negative), limited long-term human data, concerns about off-label commercial use and product quality.
What Is AOD-9604
AOD-9604 is a short synthetic peptide derived from the C-terminus of human growth hormone that was designed to reproduce GH’s fat-mobilizing (lipolytic) effects without stimulating growth of other tissues or causing the classical side effects of full-length GH. Early animal and small human studies found increased lipolysis and reduced fat accumulation; these observations motivated clinical development in obesity.
How it works in the body
Preclinical work suggests AOD-9604 increases fat breakdown and may upregulate lipolytic pathways (including effects on β-adrenergic signaling in adipose tissue) and enhance fatty-acid oxidation. Importantly, many studies report that AOD-9604 does not activate the full GH receptor pathway (so it showed minimal effects on IGF-1 and glucose homeostasis in the trials cited). Those mechanistic signals support the idea of targeted metabolic action on fat tissue rather than broad GH-like systemic effects.
AOD-9604 Benefits
- Fat metabolism and reduced fat accumulation — Animal models showed reductions in fat gain and increased lipolysis; some early human trials reported modest body-fat reductions versus placebo over short periods.
- Oral and injectable formulations tested — Development included oral dosing studies and subgroups receiving different dose levels to test practicality and tolerability.
- Minimal GH-type adverse effects in trials — Clinical safety reports indicate no clear GH-like adverse profile (no convincing IGF-1 increases or erythropoietic effects at studied doses). This was central to the peptide’s rationale.
- Preserved insulin sensitivity in preclinical work — Unlike chronic GH exposure, preclinical studies and some clinical reports did not show the same diabetogenic effects, suggesting a different safety/metabolic fingerprint.
Clinical studies
- Early animal studies and small human pilot trials (12-week trials in a few hundred subjects) produced encouraging signs: dose-dependent trends toward fat-loss and improved lipolysis in short studies.
- The program progressed into larger Phase 2b studies (the OPTIONS study; randomized, double-blind, up to 24 weeks) to test weight-loss outcomes in several hundred participants. Initial smaller cohorts showed modest effects, but the larger, longer trial did not demonstrate clinically meaningful weight loss across the whole study population, and development was subsequently halted for obesity indications.
- Overall: six human clinical trials were reported during development (IV, oral pilots, and larger oral Phase II studies). Safety signals were generally benign in trial populations, but efficacy in rigorous, large trials was inconsistent.
Safety, Side Effects, and Considerations
Safety profile observed in trials: Across the reported clinical studies AOD-9604 was generally well tolerated and produced few serious adverse events attributable to the drug; investigators reported no clear GH-like adverse pattern (no consistent increases in IGF-1 or erythropoiesis) and low immunogenicity in tested subjects.
Potential side effects and theoretical risks: While clinical reports described good tolerability, reviews and regulatory discussions noted theoretical concerns that apply to any metabolically active peptide: glucose intolerance with some GH-related fragments, off-target effects at high doses, and—when sold outside regulated channels—risks of contamination, mislabelling, and unverified dosing. Long-term safety and cancer-risk data are limited, so caution is advised.
Regulatory / development status: AOD-9604 advanced through multiple human trials but did not become an approved obesity drug following mixed efficacy in larger studies. Subsequently it has appeared in nutraceutical/commercial products in some markets, often labelled as a “research peptide” or supplement; that market path raises typical concerns about product purity and legal/regulatory status in different countries.
Practical notes & takeaways
- Evidence level: Preclinical/early clinical signals for fat-metabolism effects exist, but larger Phase II data did not consistently demonstrate robust, durable weight-loss across broad obese populations; AOD-9604 remains investigational for approved medical use.
- Safety: Short-term trials reported good tolerability and a clean safety signal relative to full-length GH, but long-term human safety data are sparse; quality control matters where products are sold commercially.
- If you’re researching this peptide: rely on peer-reviewed trial reports and regulatory statements. Avoid unverified vendors; confirm batch testing and medical supervision before considering experimental use.
